|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
|
RENAL CLEARANCE MEASUREMENT CAN NOT BE MADE WITH ACCURACY IN PATIENTS RECEIVING THIS DRUG DUE TO INTERFERENCE WITH CHEMICAL COLOR DEVELOPMENT ESSENTIAL TO ANALYTICAL PROCEDURES
|
|
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
ANTIBACTERIALS MAY INTERFERE WITH PLATELET FUNCTION OR WITH BACTERIAL SYNTHESIS OF VIT K IN THE GUT & THUS HAVE ANTICOAGULANT EFFECT OF THEIR OWN
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
POSSIBILITY OF INTERACTION WITH OTHER HIGHLY PROTEIN BOUND DRUGS LIKE NSAIDS SHOULD BE CONSIDERED
|
POSSIBILITY OF INTERACTION WITH OTHER HIGHLY PROTEIN BOUND DRUGS LIKE NSAIDS SHOULD BE CONSIDERED
|
ANTIFOLIC DRUGS SUCH AS SULPHONAMIDES SHOULD NOT BE CONCURRENTLY USED
|
CHLOROPROCAIN METABOLITE ( PARA-AMINOBENZOIC ACID) INHIBITS THE ACTION OF SULPHONAMIDES, HENCE SHOULD NOT BE CO-ADMINISTERED
|